Danish health care giant Novo Nordisk, a world leader in diabetes care, has launched an annual Changing Diabetes Barometer to create greater global awareness of the treatment of diabetes. The Changing Diabetes Barometer was presented at a press meeting last week in Brussels. Lise Kingo, executive vice president of Novo Nordisk says: "Our aim is to put diabetes on the international agenda all over the world. We don't think we can wait any longer."
The Changing Diabetes Barometer is a tool that will provide healthcare professionals, patient organisations, politicians, institutions and media with valuable information on how to improve the quality of diabetes care, combat diabetes-related complications, extend patient life expectancy and reduce costs. Novo Nordisk will collect data from around the world to compare diabetes treatment in various regions and countries.
Novo Nordisk is publishing an annual report with key results from the Changing Diabetes Barometer. The first report comprises 21 countries and highlights the fact that significant savings – as much as a 20% reduction in lifelong healthcare costs – can be made if people with diabetes are diagnosed earlier and before complications occur.
There are currently 246 million people with diabetes worldwide, a figure that is expected to increase to 380 million by 2025.
Novo Nordisk is a healthcare company and a world leader in diabetes care. It also has a leading position in haemostasis management, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 25,800 people in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London.
The news was reported by financial daily newspaper Børsen and in a Novo Nordisk press release.